Sleep, Energy & Cognition
Does DSIP (Delta Sleep-Inducing Peptide) Actually Affect Sleep?
The short answer
DSIP has been studied on and off since the 1970s, but the human evidence is thin. The one placebo-controlled trial retrieved this session — a 1992 double-blind study of 16 chronic insomniacs — found DSIP produced slightly better polysomnographic sleep efficiency and shorter sleep latency than placebo, but the authors concluded the effect was weak and 'not likely to be of major therapeutic benefit.' A single 1987 case report described DSIP correcting a delayed sleep phase in one patient. No trials of DSIP, under any name, are currently registered on ClinicalTrials.gov. A 2006 review in the Journal of Neurochemistry called the DSIP-sleep hypothesis itself 'extremely poorly documented and still weak,' and the newest research located this session is a 2021 animal study testing DSIP for stroke recovery in rats — not sleep, and not humans.
Quick answers
- What is it?
- Whether DSIP, or delta sleep-inducing peptide, actually affects sleep.
- Why are people interested in it?
- DSIP is sold online as a sleep aid, and people want to know if it's backed by real trial evidence.
- What has actually been studied?
- A single 1992 double-blind, placebo-controlled trial in 16 chronic insomnia patients, plus older case reports, reviews questioning the underlying mechanism, and a 2021 animal (rat) stroke-recovery study.
- How strong is the evidence?
- Very thin — the one placebo-controlled human trial found effects its own authors called weak and possibly not of major therapeutic benefit, and no DSIP trials of any kind are currently registered on ClinicalTrials.gov.
- What don't we know yet?
- Whether DSIP does anything meaningful for sleep at all, what DSIP's mechanism of action actually is, and whether oral or subcutaneous DSIP behaves anything like the intravenous form used in the 1992 trial.
- Where can I read the original research?
- Sources at the bottom of this page: Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. and Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
The short answer: Delta sleep-inducing peptide (DSIP) has a long research history and a very thin human evidence base. The single placebo-controlled human trial retrieved this session — a 1992 double-blind study in 16 chronic insomniacs — found DSIP produced modestly better objective sleep efficiency and shorter sleep latency than placebo, but the researchers themselves concluded the effect was weak and unlikely to be of major therapeutic benefit. Beyond that trial, the human literature consists mostly of decades-old case reports, small pharmacology studies, and reviews that questioned whether DSIP promotes sleep at all. No DSIP trials of any kind are currently registered on ClinicalTrials.gov, and the newest research located this session — a 2021 study — tested DSIP in rats after stroke, not in people, and not for sleep.
What the research shows
DSIP was isolated from rabbit cerebral venous blood in 1977 by a Swiss research group, and for a while it looked like a genuine discovery: a peptide, drawn from the blood of a sleeping animal, that seemed to induce the delta-wave (slow-wave) sleep stage when infused into other animals. Early reviews from the 1980s — including a 1984 summary in Neuroscience and Biobehavioral Reviews and a 1986 update in Peptides, both by Graf and Kastin — described DSIP inducing delta sleep in rabbits, rats, mice, and to some degree humans, with a peculiar U-shaped dose-response curve where both too little and too much peptide failed to work. Those same reviews floated DSIP as a candidate treatment for insomnia, pain, and withdrawal symptoms, but noted that its mechanism of action was still unclear.
The best human test of that promise came in 1992, when researchers in the Netherlands ran a double-blind, matched-pairs trial in 16 chronic insomnia patients. Participants slept in a lab for five nights; on three of those nights, half received an intravenous dose of DSIP (25 nmol/kg body weight) and half received a glucose placebo. Polysomnography showed DSIP produced higher sleep efficiency and shorter sleep latency than placebo, and one measure of subjective tiredness decreased in the DSIP group. But the authors were candid about the limits of what they'd found: the statistically significant effects were weak, and part of the apparent benefit might have come from an incidental change in the placebo group rather than a real drug effect. No other measure — including subjective sleep quality — changed at all. Their conclusion, in their own words, was that short-term DSIP treatment for chronic insomnia "is not likely to be of major therapeutic benefit."
Outside that trial, the human DSIP literature is largely case-report territory. A 1987 German report described a single 47-year-old woman with chronic delayed sleep phase insomnia and low-dose benzodiazepine dependence, treated with DSIP under intensive inpatient monitoring for one week. Her main sleep phase advanced by five hours, and she was able to withdraw from flunitrazepam completely — a striking result, but from one patient, unblinded, with no control condition.
By the mid-2000s, researchers working directly with DSIP had grown skeptical of the foundational premise. A 2006 review in the Journal of Neurochemistry, titled "Delta sleep-inducing peptide (DSIP): a still unresolved riddle," noted that DSIP's own gene, protein, and receptor had never been isolated, and that the link between DSIP and sleep "has never been further characterized" since the original 1977 discovery. The reviewers proposed that a different, DSIP-like peptide might be responsible for whatever biological activity had been observed — an open hypothesis, not a settled finding.
More recent DSIP research retrieved this session has moved away from sleep entirely. A 2021 study in Molecules tested intranasal DSIP in Sprague-Dawley rats after an induced stroke — this is animal data, not a human study — and found DSIP accelerated recovery of motor coordination on a rotarod test, though it didn't significantly shrink the size of the brain injury. Older animal work from the early 2000s examined DSIP's effects on stress-related brain activity in rats and its potential anti-seizure properties, also in rats — again, animal data. A 2026 review of therapeutic peptides in orthopaedics grouped DSIP with several other "recovery-enhancing" peptides, including epithalon and pinealon, and stated plainly that despite mechanistic interest, "there is a current lack of clinical trials" for the group.
That absence is confirmed by the clinical trials registry itself. A ClinicalTrials.gov search for "DSIP" and for "delta sleep-inducing peptide," run this session, returned zero results under either term — no trials recruiting, completed, terminated, or withdrawn. For a compound that's been sold online as a sleep aid for years, there is no registered U.S. clinical trial testing it against anything.
What we don't know yet
Whether DSIP does anything meaningful for sleep at all. The one placebo-controlled human trial found effects its own authors called weak and possibly artifactual. No trial has replicated or extended that finding in the more than three decades since.
What DSIP's mechanism of action actually is. DSIP's structure doesn't resemble other known peptide families, and researchers have never identified a DSIP receptor or confirmed the gene encoding it in humans — a gap flagged explicitly by the 2006 Journal of Neurochemistry review.
Whether oral or subcutaneous DSIP (how it's typically sold) behaves anything like the intravenous DSIP used in the 1992 trial. That trial delivered the peptide directly into the bloodstream; no retrieved study tested other routes of administration in a controlled human sleep trial.
Dosing, safety, and side effects in modern use. With no registered clinical trials, there is no controlled human safety data on DSIP as it is currently sold and used — only the isolated 1992 trial and a handful of older case reports and animal studies.
Whether the newer animal research on stroke recovery has any relevance to sleep. The most recent DSIP study retrieved this session tested motor recovery in rats after induced stroke, an entirely different question from sleep, and animal findings do not establish that the same effects — or any sleep effects — occur in humans.
Sources
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology, 1992;26(4):193-197. DOI
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry, 2006;97(2):303-309. DOI
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neuroscience and Biobehavioral Reviews, 1984;8(1):83-93. DOI90022-8)
- Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules, 2021;26(17):5173. DOI
- Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Global Research & Reviews, 2026;10(1). DOI
- Schneider-Helmert D, Hermann E, Schoenenberger GA. The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia [German, case report]. Deutsche Medizinische Wochenschrift, 1987;112(23):922-925. DOI
Article records maintained via PubMed. Peptide Proof reports what studies found. It does not provide medical advice, dosing guidance, or treatment recommendations.
Topic: Sleep & Recovery | Evidence Index: dsip
Sources
- Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.
- Neuropsychobiology, 1992 · n=16 · DOI
- Delta sleep-inducing peptide (DSIP): a still unresolved riddle.
- Journal of Neurochemistry, 2006 · DOI
- Delta-sleep-inducing peptide (DSIP): a review.
- Neuroscience and Biobehavioral Reviews, 1984 · DOI
- Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke.
- Molecules, 2021 · DOI
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.
- JAAOS Global Research & Reviews, 2026 · DOI
Get the evidence, not the hype.
New research briefs, plainly written and fully sourced. No dosing advice, ever.